NCT03904251View on ClinicalTrials.gov

CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 18, 2019

Primary Completion Date

October 25, 2023

Study Completion Date

October 25, 2023

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

Gemtuzumab Ozogamicin

Given IV

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

Trial Locations (5)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

92103

University of California San Diego, San Diego

92868

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

94115

UCSF Medical Center-Mount Zion, San Francisco

95817

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Jazz Pharmaceuticals

INDUSTRY

collaborator

University of California, Los Angeles

OTHER

lead

Jonsson Comprehensive Cancer Center

OTHER